(Q43067629)

13 November 2017

title

Microdose study of a P-glycoprotein substrate, fexofenadine, using a non-radioisotope-labelled drug and LC/MS/MS. (English)

1 reference

13 November 2017

A Yamazaki

1

1 reference

13 November 2017

Y Kumagai

2

1 reference

13 November 2017

N Yamane

3

1 reference

13 November 2017

Z Tozuka

4

1 reference

13 November 2017

Y Sugiyama

5

1 reference

13 November 2017

T Fujita

6

1 reference

13 November 2017

S Yokota

7

1 reference

13 November 2017

M Maeda

8

1 reference

13 November 2017

publication date

1 April 2010

1 reference

Journal of Clinical Pharmacy and Therapeutics

13 November 2017

published in

1 reference

13 November 2017

volume

35

1 reference

13 November 2017

issue

2

1 reference

13 November 2017

page(s)

169-175

1 reference

Can the pharmaceutical industry reduce attrition rates?

13 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01159.X

The price of innovation: new estimates of drug development costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01159.X

Early microdose drug studies in human volunteers can minimise animal testing: Proceedings of a workshop organised by Volunteers in Research and Testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01159.X

Big physics, small doses: the use of AMS and PET in human microdosing of development drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01159.X

Current perspectives of 14 C-isotope measurement in biomedical accelerator mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01159.X

Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01159.X

Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01159.X

Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01159.X

Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01159.X

P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01159.X

Functional Characterization of pH-Sensitive Organic Anion Transporting Polypeptide OATP-B in Human

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01159.X

Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01159.X

Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01159.X

Inhibition of oat3-mediated renal uptake as a mechanism for drug-drug interaction between fexofenadine and probenecid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01159.X

Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01159.X

Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01159.X

The effect of rifampin administration on the disposition of fexofenadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01159.X

Effect of St John's wort on the pharmacokinetics of fexofenadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01159.X

Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01159.X

Transport characteristics of fexofenadine in the Caco-2 cell model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2710.2009.01159.X

10.1111/J.1365-2710.2009.01159.X

21 January 2018

Identifiers

DOI

1 reference

13 November 2017

1 reference